[The effects of aranidipine on ambulatory blood pressures in patients with mild to moderate essential hypertension].

Abstract

OBJECTIVE:

To evaluate the effect of aranidipine enteric-coated capsules on 24 h blood pressure and blood pressure variability (BPV) in patients with mild to moderate essential hypertension.

METHODS:

This was an open clinical trial with 2 weeks of placebo run-in period. A total of 74 patients with blood pressure (140-180/95-110 mm Hg (1 mm Hg = 0.133 kPa) were treated by aranidipine (5 mg/d) for 4 weeks.If clinical sitting blood pressure < 140/90 mm Hg at 4th week, aranidipine at 5 mg/d would be continued for another 8 weeks.If not, the dosage would be increased to 10 mg/d.If blood pressure <140/90 mm Hg at 8th week, aranidipine at 5 mg/d or 10 mg/d would be given constantly.If not, the dosage would be increased to 20 mg/d and given for another 4 weeks. All patients performed 24 h ambulatory blood pressure monitoring (ABPM) before and after the treatment with BPV evaluated by the average 24 h per unit time blood pressure standard deviation and morning blood pressure surge (MBPS).

RESULTS:

(1) After 12 weeks' treatment with aranidipine, the mean 24 h blood pressure was reduced significantly compared with the baseline [(14 ± 13)/(11 ± 9) mm Hg, both P < 0.05] with trough/peak (T/P) ratio of SBP and DBP in responders of 75.31% and 78.15%, respectively.(2) After 12 weeks' treatment, standard deviations of 24 h, daytime SBP/DBP and nighttime SBP/DBP were reduced significantly[(25 ± 3)/(14 ± 4) mm Hg vs (11 ± 3)/(8 ± 2) mm Hg, (24 ± 5)/(14 ± 4) mm Hg vs (11 ± 3)/(8 ± 2) mm Hg, (10 ± 3)/(8 ± 4) mm Hg vs (8 ± 3)/(6 ± 3) mm Hg], respectively with all P < 0.05.Significant decrease was shown in MBPS compared to the baseline [(27 ± 11) mm Hg vs (19 ± 9) mm Hg, P < 0.05]. (3) The incidence of adverse events was 13.4%, including mild dizziness, flushing and palpitation.

CONCLUSION:

Administration of aranidipine enteric-coated capsules can control 24 h blood pressure effectively and reduce BPV significantly in patients with mild to moderate essential hypertension with good safety profile.

• Authors: Li Chen, Hong Jiang, Qi Hua, Han-yue Yang, Jia-tong Zheng, Hao Jin, Yuan Jiao, Yun Wang, Rui-hua Sun, Yuan-nan Ke
• Journal: Zhonghua nei ke za zhi (Zhonghua Nei Ke Za Zhi) Vol. 52 Issue 9 Pg. 749-52 (Sep 2013) ISSN: 0578-1426 [Print] China
• PMID: 24314165 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antihypertensive Agents
• Dihydropyridines
• aranidipine

Topics

• Adolescent
• Adult
• Aged
• Antihypertensive Agents (administration & dosage, therapeutic use)
• Blood Pressure (drug effects)
• Blood Pressure Monitoring, Ambulatory
• Dihydropyridines (administration & dosage, therapeutic use)
• Essential Hypertension
• Female
• Humans
• Hypertension (drug therapy)
• Male
• Middle Aged
• Young Adult